Skip to main content

MARCADORES DEL NEURODESARROLLO Y ESQUIZOFRENIA: ANALISIS DE VARIABILIDAD GENETICA COMPARTIDA Y DEL EFECTO DEL ESTRES PRENATAL

PI20/01002

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION Y DOCENCIA MARIA ANGUSTIAS GIMENEZ (FIDMAG)
Execution centre BENITO MENNI COMPLEX ASSISTENCIAL EN SALUT MENTAL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Theory of mind in schizophrenia through a clinical liability approach, a sib-pair study

  • Giralt López, Maria|||0000-0003-4555-152X
  • Miret, S.
  • Campanera, Silvia
  • Moreira, Marco Antonio
  • Sotero-Moreno, A.
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Fañanás Saura, Lourdes
  • Fatjó-Vilas, Mar|||0000-0001-9963-6241
Consistent findings indicate that Theory of Mind (ToM) is impaired in schizophrenia (SZ). To investigate whether such deficits are trait- or state-dependent, we investigated if ToM is modified by clinical liability markers (such as basic symptoms and psychotic-like experiences), focusing on the analysis of unaffected siblings of individuals diagnosed with SZ. The study included a total of 65 participants: 38 patients diagnosed with a schizophrenia-spectrum disorder and 27 healthy siblings. ToM was assessed using the Hinting Task (HT), Basic symptoms with The Frankfurt Complaint Questionnaire (FCQ), Psychotic-like-experiences with the Community Assessment of Psychic Experiences (CAPE) and Family history with the Family Interview for Genetic Studies. First, a comparison of HT performance between patients and siblings (linear mixed model adjusted for age, sex and Intelligence Quotient (IQ)) showed that patients presented lower scores than siblings (p = 0.022). These differences did not remain significant after adjusting for clinical vulnerability markers. Second, within siblings, linear regression analyses (adjusted for age, sex, IQ and family history) showed that higher FCQ Depressiveness and CAPE negative scores were related to poorer ToM performance (p = 0.007 and p = 0.032, respectively). Our findings suggest that clinical liability markers are valuable for delineating variations in ToM capabilities within healthy individuals. Moreover, our results indicate that ToM deficits are not solely linked to SZ but also extend to its clinical vulnerability, suggesting that ToM could serve as an endophenotypic marker. This implies that ToM could help distinguish particularly susceptible individuals from a population at risk, such as those with a genetic predisposition (siblings).